Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04904120
Other study ID # TIMAR1
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 5, 2021
Est. completion date September 20, 2022

Study information

Verified date June 2022
Source Viewpoint Molecular Targeting
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.


Description:

This is a first-in-human study evaluating the suitability of [203Pb]VMT01 for SPECT/CT imaging and [68Ga]VMT02 for PET/CT imaging of MC1R-expressing metastatic melanoma. Study results will provide foundational data to develop imaging and dosing for future therapeutic trials of [212Pb]VMT01 for the treatment of metastatic melanoma. The study will be a cross-over study with the participants serving as their own comparator. Participants with positive FDG-PET scans for stage IV (or inoperable stage III) metastatic melanoma will undergo SPECT/CT scans utilizing [203Pb]VMT01 followed a few weeks later by PET/CT scans utilizing [68Ga]VMT02, or vice versa. The order of the imaging agents will be randomly assigned.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date September 20, 2022
Est. primary completion date September 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: 1. Diagnosed with Stage IV metastatic melanoma, or inoperable Stage III equivalent 2. Baseline fluorodeoxyglucose (FDG)-PET scan available from within 30 days prior to date of enrollment 3. Blood counts and metabolic results within protocol limits within 14 days prior to enrollment 4. Ability to lie flat and still for a minimum of two hours for imaging 5. Male and female participants with reproductive potential must agree to use highly effective contraception in preparation of the study, during the study, and for 4 weeks following the last dose of an investigative imaging agent 6. Documented life expectancy of at least 3 months Exclusion Criteria: 1. Active secondary malignancy 2. Prior treatment (for any reason) with radioactive nuclides; imaging tracers are acceptable 3. Pregnancy or breast feeding a child 4. Uncontrolled infection 5. Treatment with another investigational drug within 30 days prior to enrollment date 6. Any treatment with BRAF inhibitors since the baseline FDG-PET scan or plans for such treatment during the study 7. Kidney function not within protocol limits 8. BMI>40 kg/m2 9. History of a condition resulting in anaphylaxis or angioedema

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
[203Pb]VMT01
Diagnostic imaging radiopharmaceutical; by intravenous infusion
[68Ga]VMT02
Diagnostic imaging radiopharmaceutical; by intravenous infusion

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Viewpoint Molecular Targeting Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Study Imaging Agent-Associated Adverse Events (AE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Adverse Events (AEs) will be assessed for severity according to CTCAE v5.0 and for relatedness to each of the investigative imaging agents ([203Pb]VMT01 and [68Ga]VMT02). Assessments attributed as possibly, probably, or definitely related to the imaging agent will be considered related. Visit 1 (Day 1) through Visit 5 (approximately Day 60 but could extend up to Day 108); ongoing Serious Adverse Events (SAE) will be followed for no longer than Day 65 or 30 days from the date of the SAE report (whichever is later).
Primary Biodistribution of [68Ga]VMT02 Biodistribution will be calculated by utilizing PET/CT scans. 12 hours
Primary Biodistribution of [203Pb]VMT01 Biodistribution will be calculated by utilizing SPECT/CT scans. 24 hours
Primary Peak Plasma Concentration (Cmax) of [203Pb]VMT01 Cmax will be determined by blood sampling and direct radioactivity measurements. 24 hours
Primary Area Under the Plasma Concentration Versus Time Curve (AUC) for [203Pb]VMT01 AUC will be determined by blood sampling and direct radioactivity measurements. 24 hours
Primary Renal Excretion of [203Pb]VMT01 Renal excretion will be determined by urine sampling and direct radioactivity measurements. 24 hours
Primary Modeling of [203Pb]VMT01 Dosimetry Dosimetry will be modeled by utilizing the SPECT/CT scans. 24 hours
Secondary MC1R Expression Correlation Between Archived Tumor Tissue and Study Imaging Archived (previously collected) tumor tissue will be tested for MC1R expression and compared to study images obtained using MC1R targeted imaging agents, [203Pb]VMT01 and [68Ga]VMT02. The data will be assessed for an association between positive tissue and positive images. Historical tissue sample (collected <365 days before study enrollment) compared to Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging
Secondary Cancer Site Correlation Between Standard of Care Imaging Compared to Study Imaging Sites of cancer detected previously by imaging will be compared to the presence or absence of positive imaging scans with the study agents, [203Pb]VMT01 and [68Ga]VMT02. Historical imaging information compared to Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging
Secondary Dosimetry will be Calculated for each Study Imaging Agent by Measuring the Cumulative Absorbed Dose of Radiation to the Participant's Individual Organs and Tumors For a given participant, dosimetry calculations will be compared between the two imaging agents with respect to cumulative absorbed dose of radiation. Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging
See also
  Status Clinical Trial Phase
Completed NCT04062032 - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma Phase 2
Completed NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Completed NCT00962845 - Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery Early Phase 1
Completed NCT00324623 - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma Phase 1
Completed NCT00104845 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 1
Completed NCT00096382 - Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00072085 - Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00072124 - Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Phase 3
Completed NCT00089193 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 2
Active, not recruiting NCT00039234 - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Phase 3
Completed NCT00042783 - Vaccine Therapy in Treating Patients With Stage IV Melanoma Phase 2
Completed NCT00049010 - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma N/A
Completed NCT00005610 - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Phase 2
Completed NCT00006385 - Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00020358 - Vaccine Therapy in Treating Patients With Melanoma Phase 2
Completed NCT00006022 - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer Phase 1
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Withdrawn NCT00006126 - Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery Phase 1